(Q35906903)

11 August 2017

1 reference

title

Assessing the efficacy of medical treatments for alcohol use disorders (English)

1 reference

11 August 2017

0 references

Darlene H Moak

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

10

1 reference

11 August 2017

page(s)

2075-2089

1 reference

Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National Survey of Mental Health and Well Being

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Genetics of the risk for alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Alcohol and genetics: new models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Outcome predictors in substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Management of drug and alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Management of the alcohol withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre doubl-blind comparison with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Gamma-hydroxybutyric acid and alcohol-related syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

The use of divalproex in alcohol relapse prevention: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Pharmacotherapies for alcohol abuse. Withdrawal and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Neuropharmacological treatments for alcoholism: scientific basis and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

The effects of naltrexone on alcohol and cocaine use in dually addicted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Depot naltrexone: long-lasting antagonism of the effects of heroin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Polymorphisms in the N-methyl-D-aspartate receptor 1 and 2B subunits are associated with alcoholism-related traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Alcohol and Central Serotonin Metabolism in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Reduced central serotonin turnover in a subgroup of alcoholics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Baclofen administration for the treatment of affective disorders in alcoholic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Alcohol dependence and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Impact of substance abuse on the course and treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Potential use of olanzapine in treatment of substance dependence disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Quetiapine for alcohol use and craving in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Alcohol abuse in individuals exposed to trauma: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Treatment of schizophrenia and comorbid substance use disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Patient Attitudes toward Treatment Predict Attendance in Clinical Pharmacotherapy Trials of Alcohol and Drug Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2075

10.1517/14656566.5.10.2075

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference